60 Degrees Pharmaceuticals (NASDAQ: SXTP) — Perfil da empresa, notícias e dados financeiros
60 Degrees Pharmaceuticals develops treatments for tropical diseases like malaria and dengue.
60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals (NASDAQ:SXTP) is primarily focused on the development and commercialization of pharmaceutical products designed for the prevention and treatment of tropical diseases, including malaria and dengue. Their operations span from research and development to navigating regulatory approvals and forging key partnerships for distribution and sales. One of the prominent projects includes the development of Tafenoquine, a novel compound designed for the prevention of relapsisng malaria. With an overarching objective to address unmet medical needs in tropical medicine, 60 Degrees Pharmaceuticals is committed to leveraging scientific advancements to improve global health outcomes.
Resumo
Operações
Produtos e/ou serviços de 60 Degrees Pharmaceuticals
- Arakoda (Tafenoquine): This is their only commercially available product, launched in late 2019. Arakoda is a single-dose prescription medication used to prevent malaria in adults and children 16 years of age and older.
- New Products Containing the Arakoda Regimen of Tafenoquine: The company is exploring using Tafenoquine, the active ingredient in Arakoda, for additional applications beyond malaria prevention.
- Celgosivir: This drug candidate is being developed for the treatment of COVID-19, though it is still in the pre-clinical trial stage.
- Clinical Trial Support: They might provide support for clinical trials related to their pipeline medications. This could involve sponsoring trials, collaborating with research institutions, or supplying medication for testing purposes.
- Partnerships for Development: 60 Degrees Pharmaceuticals might partner with other companies or research institutions to leverage expertise or resources during the development of new drugs.
- Disease Awareness Initiatives: They potentially contribute to raising awareness about infectious diseases like malaria, which aligns with their core mission.
equipe executiva do 60 Degrees Pharmaceuticals
- Geoffrey Stuart DowChairman, CEO & President
- Tyrone MillerChief Financial Officer
- Kristen LandonChief Commercial Officer
- Bryan SmithChief Medical Officer
Últimas notícias sobre a 60 Degrees Pharmaceuticals
60 Degrees Pharma reports positive safety update from Phase 2 babesiosis study
United States60 Degrees Pharmaceuticals expands ARAKODA access via Runway Health telehealth partnership
United States60 Degrees Pharmaceuticals reports 65% revenue surge as pharmacy partnerships expand access
United States60 Degrees Pharmaceuticals reports 100% cure rate in relapsing babesiosis trial
United States
Principais indicadores financeiros
Resultados divulgados pela 60 Degrees Pharmaceuticals , em USD.
- Cap. de mercado
- 2,6 mi
- Receita (TTM)
- 1,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -5.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1 mi | -7,8 mi | -7,4 mi | |
| 607,6 mil | -9,7 mi | -7,9 mi | |
| 253,6 mil | -5,2 mi | -3,8 mi | |
| 223,2 mil | -1,8 mi | -6,2 mi |